ライフサイエンスコーパス: renoprotection

1 tially viable mechanism for AFSC-EV mediated renoprotection.

2 minuria, implying that canagliflozin confers renoprotection.

3 e AFSC could be responsible for the observed renoprotection.

4 nd their dual action seems to confer greater renoprotection.

5 ent with metformin, did not provide complete renoprotection.

6 tion similarly abolishes PGC1alpha-dependent renoprotection.

7 ith a single dose of UA afforded significant renoprotection against ischemic injury.

8 epresents a potential therapeutic target for renoprotection and prevention of fibrosis following acut

9 ial to signal injury and afford postischemic renoprotection and repair remains obscure.

10 n angiotensin-converting enzyme inhibitor on renoprotection and survival in 250 patients with hyperte

11 ent studies have not detected differences in renoprotection between ARB and ACEI.

12 ce, recent clinical trials have demonstrated renoprotection by angiotensin II inhibition in patients

13 ta demonstrating the physiologic evidence of renoprotection by antihypertensive therapy.

14 However, vitamin D may also promote renoprotection by suppressing renin transcription throug

15 a-globin gene locus in SSA patients confers "renoprotection" by mechanisms not related to the degree

16 animal models of chronic renal injury, such renoprotection can virtually eliminate progression of th

17 ult, suggesting that the previously reported renoprotection conferred by MSU likely results from exoc

18 r an S1P(1)R antagonist, suggesting that the renoprotection conferred by S1P(2)R antagonism results f

19 endogenous mediator of EPC mobilization and renoprotection, consistent with its novel function in ph

20 ation/transplantation, and suggest that this renoprotection correlates with decreased membrane lipid

21 mia-reperfusion injury and suggest that this renoprotection correlates with late vasodilatory prostan

22 This renoprotection corresponded with increases in cytoprotec

23 The extent of renoprotection, decrease in cellular p53 and attenuation

24 Whether this renoprotection derives from a reduction of macrophages a

25 icity, which can be effectively targeted for renoprotection during chemotherapy.

26 geting PKCdelta as an effective strategy for renoprotection during cisplatin-based cancer therapy.

27 MitoQ showed renoprotection equivalent to ramipril but no synergistic

28 The role of lipid-lowering treatments in renoprotection for patients with diabetes is debated.

29 In humans with chronic renal injury, renoprotection has been successfully demonstrated only l

30 volved are largely unknown, and HIF-mediated renoprotection has not been examined in other causes of

31 y, xenon provided morphologic and functional renoprotection; hydrodynamic injection of HIF-1alpha sma

32 uding maximal ACE inhibition affords greater renoprotection in diabetic nephropathy despite a similar

33 inferior to enalapril in providing long-term renoprotection in persons with type 2 diabetes.

34 profile using juniper oil (JO) would afford renoprotection in rats treated with tacrolimus.

35 r injury may be reversible, the HIF-mediated renoprotection in VHL-KO mice was associated with activa

36 nsin receptor blockers achieves only partial renoprotection, increasing the need for novel therapeuti

37 Whether this renoprotection involves enhanced GLP-1 signaling is uncl

38 Conversely, renoprotection is conferred by processes that upregulate

39 Interest in pharmacologic renoprotection is currently directed toward statins and

40 n D signaling in podocytes accounts for this renoprotection is unknown.

41 ieved appears to be the major determinant of renoprotection, not the class of drug used.

42 onstrated for the first time that Xe confers renoprotection on renal grafts ex vivo and is likely to

43 , and there is uncertainty about the greater renoprotection seen in non-diabetic renal disease.

44 in this model, OMA affords greater long-term renoprotection than ENA when doses are adjusted to yield

45 sartan conferred similar (i.e., noninferior) renoprotection to 10 to 20 mg of enalapril as determined

46 In Model 1 maximal renoprotection was demonstrated with the 6 mg/kg dose of